A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes

References

• Goff DC Jr, D’Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264–70
   Google Scholar
• Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453–62
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143–421
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care 2007;30:S4–41
   PubMedGoogle Scholar
• National Committee for Quality Assurance. P4P Measurement Year 2006 Clinical Specifications November Updates. Available at http://web.ncqa.org/LinkClick.aspx?fileticket=DTP8daVLz7c%3D&tabid=212&mid=1153&forcedownload=true. Accessed 3/30/07
   Google Scholar
• Bottorff MB. Underidentification and undertreatment issues. J Manag Care Pharm 2003;9:6–8
   PubMedGoogle Scholar
• Kristensen J, Lauritzen T. Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County. Scand J Prim Health Care 2006;24: 181–5
   PubMed Web of Science ®Google Scholar
• Primatesta P, Pouter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol 2006;64:292–8
   PubMed Web of Science ®Google Scholar
• Wilder LB, Bachorik PS, Finney CA, et al. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med 1995;99:374–7
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Audelin MC, McNamara JR, et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 2001;88: 1129–33
   PubMed Web of Science ®Google Scholar
• Weiss R, Harder M, Rowe J. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methyl glutaryl-coenzyme A reductase inhibitors. Clin Ther 2003;25: 1490–7
   Google Scholar
• Bittner V. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 2004;7:122–6
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326–33
   PubMed Web of Science ®Google Scholar
• Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27:1991–7
   PubMed Web of Science ®Google Scholar
• Wagner AM, Perez A, Zapico E, Ordonez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003;26: 2048–51
   Google Scholar
• Liu J, Sempos C, Donahue R, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005;28:1916–21
   PubMed Web of Science ®Google Scholar
• Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000;15:395–9
   PubMed Web of Science ®Google Scholar
• Kuller L, Arnold A, Tracy R, Otvos, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175–80
   PubMed Web of Science ®Google Scholar
• El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547–53
   PubMed Web of Science ®Google Scholar
• Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930–7
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;28;113:1556–63
   Google Scholar
• Roeters van Lennep JE, Westerveld HT, van Roeters Lennep HWO, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events, Arterioscler Thromb Vasc Biol 2000; 20:2408–13
   PubMed Web of Science ®Google Scholar
• Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847–70
   Google Scholar
• Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal triglyceride levels. J Clin Endocrin 2004;89:2153–9
   PubMed Web of Science ®Google Scholar
• Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988;34:2456–9
   Google Scholar
• Ragland BD, Konrad RJ, Chaffin C, et al. Evaluation of a homogeneous direct LDL-cholesterol assay in diabetic patients: effect of glycemic control. Clin Chem 2000;46: 1848–51
   PubMed Web of Science ®Google Scholar
• Nauck M, Graziani MS, Bruton D, et al. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clin Chem 2000;46: 506–14
   PubMed Web of Science ®Google Scholar
• Ambus T, Korogyi N, DeCampos F, et al. Evaluation of the Beckman Synchron CX4 clinical chemistry analyzer in a hospital laboratory. J Clin Lab Anal 1990; 4:120–5
   PubMed Web of Science ®Google Scholar
• Bairaktari E, Hatzidimou K, Tzallas C, et al. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem 2000;33:549–55
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Social Services. Medicare, Medicaid, and CLIA Programs: Regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Final Rule. Fed Regist 1992;57: 7002–186
   Google Scholar
• Mora S, Szklo M, Otvos JD, et al.. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211–17
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Otvos JD. Heterogeneity of low-density lipo-protein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol < 00 mg/dl. Am J Cardiol 2006;98:1599–602
   PubMed Web of Science ®Google Scholar
• Rosenthal MB, Landon BE, Normand SL, et al. Pay for performance in commercial HMOs. N Engl J Med. 2006;355:1895–902
   PubMed Web of Science ®Google Scholar
• Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006;355:375–84
   PubMed Web of Science ®Google Scholar
• CM. Bell and W. Levinson. Pay for performance: learning about quality. Can Med Assoc J 2007;176:1717–19
   Web of Science ®Google Scholar